Pharma Marketing Network

A friend, who shall remain anonymous, wrote:"I notice you’ve been giving attention to the Lunesta mascot."Their problem is, they got the wrong Luna Moth."You...

This morning, Peter Rost -- Pfizer whistleblower and anti-drug industry blogger -- appeared live on Fox Business News, which as we all know is...

"It's way too recognizable," Adrian Adams, Sepracor’s ceo, told Ed Silverman, Pharmalot's journalist blogger, about the Lunesta moth mascot.Recall that I had previously predicted...

I just received this e-mail from AstraZeneca, which indicates how it is currently using eMarketing to reach out to me and untold millions of...

"As concerns about the economy mount, some ad agencies and media-buying firms already have begun some belt-tightening" (WSJ: "Spending Trimmed for Slower Times").A chart...

Massachusetts and several other states have put either banned all gifts to physicians by pharmaceutical companies, placed limits on gifts, or or considering doing so. At least 'sunshine' acts have been proposed in Congress as well. This article reviews some aspects of these 'sunshine' laws and focuses on a recent CALPIRG analysis of drug company gifts to physicians.

Massachusetts and several other states have put either banned all gifts to physicians by pharmaceutical companies, placed limits on gifts, or or considering doing so. At least 'sunshine' acts have been proposed in Congress as well. This article reviews some aspects of these 'sunshine' laws and focuses on a recent CALPIRG analysis of drug company gifts to physicians.

Guerrilla marketing has been known to close down a whole city (Boston) and thereby draw tremendous media attention to the brand being promoted. But is this a tactic that is appropriate for pharmaceutcal products?

TNS Healthcare research suggests that you can enhance your chances of building a blockbuster brand by developing a customer-driven approach that focuses more on building relationships with physicians than does the traditional detailing model. In support of this, TNS surveyed primary care physicians in the US and 5 European countries. The results are summarized in this article.

With all the new attention being paid to drug risks, it is time to take a look at the issues surrounding drug risk communication to consumers and patients. Pharmaceutical marketers need to understand these issues to better communicate risk and build trust in their brands.